

3 B7-2 protein and a B7-2 extracellular domain polypeptide or an effective fragment of said  
4 polypeptide.

1 20. (Amended) The pharmaceutical composition of [any of] claim[s 17 to] 19 wherein the  
2 CD 28 agonist is an anti-CD28 agonist antibody.

1 23. (Amended) The pharmaceutical composition of [any of] claim[s] 17 [to 22] wherein the  
2 autoimmune disease is selected from the group consisting of autoimmune diabetes, multiple  
3 sclerosis, myasthenia gravis, rheumatoid arthritis, Hashimoto's thyroiditis, Sjogren syndrome  
4 and systemic lupus erythematosus.

1 27. (Amended) The pharmaceutical composition of [any of] claim[s] 25 [or 26] wherein the  
2 CD28 agonist is selected from the group consisting of an anti-CD28 agonist antibody, human  
3 B7-2 protein and a B7-2 extracellular domain polypeptide or an effective fragment of said  
4 polypeptide.

1 28. (Amended) The pharmaceutical composition of [any of] claim[s 25 to] 27 wherein the  
2 agonist is an anti-CD28 agonist antibody.

1 31. (Amended) The pharmaceutical composition of [any of] claim[s] 25 [to 30] wherein the  
2 tissue transplant is selected from the group consisting of a kidney transplant, a heart transplant,  
3 a pancreas transplant, a pancreatic islet transplant and a liver transplant.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this  
Application are in condition for examination.